What You Missed in 2024
The ONLY event dedicated to macrophage therapeutics & applications beyond oncology
The 6th Macrophage-Directed Therapies Summit united biopharma and academia leaders across R&D, Discovery, Biology, Translational, and Clinical Development to confront the most pressing challenges in the space, with crucial discussions on the current investment landscape, giving you the information needed to secure strategic partnerships and navigate the evolving funding environment.
Despite toxicity concerns for CD47 targets in 2023, the macrophage community understands the critical importance of advancing revolutionary treatments for oncology, autoimmunity, inflammation, neurodegenerative disorders, and beyond, making this work more vital than ever.
Joining a community that prevails
Meeting top leaders
This was your chance to gain first-hand knowledge and network with top institutions like Carisma Therapeutics, Resolution Therapeutics, Harvard Medical School, and Johns Hopkins School of Medicine, as they unravelled the latest discoveries in macrophage biology and drove us closer to proof-of-concept data.
Key Highlights of 2024
Assessing the evolving macrophage-therapeutics landscape to uncover innovative targets and the latest data
Exploring indications for extending beyond oncology to autoimmunity, inflammation, and neurodegenerative diseases
Discussing novel approaches that promise to pioneer the next generation of CAR-M therapies
Download the 2024 Agenda for More Information on:
-
-
-
- 28+ Macrophage Expert Speakers
- 3 Interactive Deep-Dive Workshops
- 8+ Hours of Industry Networking
- & Much More!
-
-
World-Class Speaker Faculty Included
2024 Partners
Explore Related Cell Therapy Products
Cell Therapy
Delivering Safer, More Effective & Globally Accessible Cell Therapies to Patients at Scale
Conferences
Our Cell Therapy conferences aim to supercharge durable, safe, and cost-effective cell therapies for patients. We focus on helping overcome the discovery, translational, clinical, and commercial hurdles to realize cell therapies for patients at scale.
Data
Beacon's cell therapy database covers trial and drug records for preclinical, active, approved, and discontinued CAR (chimeric antigen receptor) modified therapies, TCR (T-Cell Receptor) therapies, natural killer cells, tumor-infiltrating lymphocytes cytokine-induced killer cells, dendritic cells, and macrophages.
Networking
A year-round experience-sharing and problem-solving network helping drug developers address critical R&D challenges in CAR-TCR therapies for solid tumors.
Research
A trusted provider of market intelligence for anyone looking to understand the complexities of cell therapy research and development.